Cancer treatment in India just got a little more affordable. From today, 9 November 2026, revised prices for 137 anti-cancer medicines have come into effect, after the drug pricing regulator capped the trade margin on these drugs at 30 per cent. The government says patients could save an estimated Rs 3,540 crore a year.
The move covers some of the most expensive medicines in Indian healthcare, including immunotherapy drugs used for more than 20 types of cancer. For families already stretched by hospital bills, even a partial cut can make a real difference. But the relief is not uniform, and some of the costliest patented drugs have not become cheaper at all.
What changed from today
The National Pharmaceutical Pricing Authority (NPPA) notified the order on 17 October 2026, under Paragraph 19 of the Drugs (Prices Control) Order, 2013. It limits the trade margin, the gap between a distributor’s buying price and the maximum retail price (MRP), to 30 per cent of the MRP, excluding GST.
The cap applies to 137 non-scheduled anti-cancer drugs, across all strengths, forms and combinations, including patented medicines. The list was drawn up by an expert committee of the Directorate General of Health Services. It includes immunotherapies such as pembrolizumab, durvalumab and osimertinib, besides denosumab, pegfilgrastim and bevacizumab, used in colorectal, ovarian, breast and prostate cancers.
As of 8 November, 85 companies had reported revised MRPs for 1,364 formulations covering 121 of the 137 drugs. Of these, 679 brands saw MRPs fall by more than 50 per cent. The largest single cut reported was 96.45 per cent.
How much cheaper will medicines get
The NPPA expects the cap to bring MRPs down by up to 70 per cent, depending on how high the existing margin was on each product. The Department of Pharmaceuticals put the estimated annual saving for consumers at Rs 3,540.38 crore.
That is an estimate, not money already saved. What a patient actually saves depends on the drug, the brand and whether the pharmacy is selling old stock or a new batch.
- New batches will carry the revised MRP printed on the pack.
- Old stock already in shops will continue to sell at the earlier price until it is replaced.
- 679 brands have reported price cuts of more than 50 per cent.
- Biggest reported cut: 96.45 per cent on one formulation.
The catch: some expensive drugs are unchanged
The price cut does not help every patient equally. The cap only lowers an MRP where the existing trade margin was above 30 per cent. Brands already within that limit see no change, and several patented drugs fall in that group.
An analysis cited by The Indian Express found that across 643 formulations studied, the average reduction was under 40 per cent, and 159 formulations saw no price change at all, including all the patented drugs in the analysis. Pembrolizumab, sold as Keytruda by MSD and used to treat at least 18 types of cancer, remained unchanged at Rs 2.17 lakh per vial. Over half of the unchanged formulations cost more than Rs 1 lakh per pack.
The Organisation of Pharmaceutical Producers of India has supported the order, saying it could improve affordability. Patient groups say the real test will be whether the new prices actually appear on pharmacy bills in the coming weeks.
How to check your medicine’s new price
Patients can verify the revised price before paying on the NPPA website or its Pharma Sahi Daam app, available on Android and iOS. Hospitals, pharmacies and companies must display the revised MRP on their websites.
If a chemist charges more than the revised MRP on a new batch, raise it with the NPPA or the state drug controller. Keep the bill and the pack, since the printed MRP and batch number establish which price applies.
The Supreme Court is also examining whether similar price controls should extend beyond cancer medicines. For now, the immediate change is the one that takes effect today: 137 cancer drugs with a capped trade margin, and lower printed prices on hundreds of formulations.
FAQs
Which cancer drugs have become cheaper from 9 November 2026?
Revised prices cover 137 non-scheduled anti-cancer drugs, 1,364 formulations reported so far, including immunotherapy drugs and medicines such as denosumab, pegfilgrastim and bevacizumab.
By how much have cancer drug prices fallen?
MRPs are expected to fall by up to 70 per cent. Of the formulations reported, 679 brands saw cuts of more than 50 per cent, and the largest single cut was 96.45 per cent. The average reduction, however, was under 40 per cent.
Why is my medicine still the same price?
Old stock still sells at the earlier MRP, and some brands, including patented drugs such as pembrolizumab, were already within the 30 per cent margin limit, so their prices did not change. Check the batch on the pack and the revised price on the Pharma Sahi Daam app.
How much will patients save overall?
The government estimates annual savings of about Rs 3,540.38 crore once the revised prices are fully in effect. The actual saving depends on the drug, the brand and how quickly new stock replaces old stock.
Cancer care in India remains expensive, and a price cap is only one part of the bill. But for lakhs of families buying these drugs month after month, today is a step towards treatment that costs a little less.
